Back to top
more

VAREX IMAGING (VREX)

(Delayed Data from NSDQ)

$15.63 USD

15.63
588,224

+0.04 (0.26%)

Updated May 6, 2024 04:00 PM ET

After-Market: $15.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Investors Undervaluing VAREX IMAGING (VREX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

VREX vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

VREX vs. LMAT: Which Stock Is the Better Value Option?

Implied Volatility Surging for Varex Imaging (VREX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Varex Imaging (VREX) stock based on the movements in the options market lately.

VAREX IMAGING (VREX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of 52.38% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.21% and 97.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate VAREX IMAGING (VREX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

VAREX IMAGING (VREX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.

Avantor (AVTR) to Improve Biopharma Supply Chain With New Site

by Zacks Equity Research

Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.

Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.

Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence

by Zacks Equity Research

Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

by Zacks Equity Research

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

CVS Health (CVS) Scales a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).

Hologic (HOLX) Reports New Findings on Breast Cancer Index

by Zacks Equity Research

Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.

Here's Why You Should Hold on to Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Thermo Fisher (TMO) Completes Acquisition of Leading CRO

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth

by Zacks Equity Research

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay

by Zacks Equity Research

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.

Change Healthcare (CHNG) Cloud-Native PACS Now in Clinical Use

by Zacks Equity Research

The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.

Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection

by Zacks Equity Research

Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.